BI655130 Single Dose in Generalized Pustular Psoriasis
Status:
Completed
Trial end date:
2018-01-10
Target enrollment:
Participant gender:
Summary
This is a phase I, open label, single group study that is being performed to assess the
safety, tolerability, Pharmacokinetics (PK) , Pharmacogenomics (PGx) and efficacy of a single
dose of BI 655130 in adult patients with active Generalized Pustular Psoriasis (GPP).